Skip to main content

Table 3 FDG and 4DST PET parameters pre- and post-neoadjuvant therapy, comparing between responders and non-responders (median, (interquartile range))

From: Efficacy of 4′-[methyl-11C] thiothymidine PET/CT before and after neoadjuvant therapy for predicting therapeutic responses in patients with esophageal cancer: a pilot study

Parameters

Responders

Non-responders

p value

FDG

preSUVmax

16.9 (13.1, 19.5)

10.0 (8.0, 13.9)

0.018

postSUVmax

4.5 (3.2, 5.4)

6.1 (4.2, 7.9)

0.11

 ΔSUVmax (%)

− 72.6 (− 78.4, 67.2)

− 36.3 (− 49.9, − 18.7)

< 0.001

preMTV

18.7 (7.09, 32.9)

8.7 (4.6, 25.3)

0.29

postMTV

3.1 (2.1, 6.9)

2.5 (1.8, 5.6)

0.75

 ΔMTV (%)

− 70.4 (− 86.1, − 60.6)

− 59.1 (− 76.2, − 45.7)

0.27

preTLG

150.5 (70.8, 249.8)

38.3 (19.6, 160.8)

0.14

postTLG

8.7 (5.4, 23.7)

12.8 (6.3, 23.5)

0.60

 ΔTLG (%)

− 90.2 (− 95.1, − 86.2)

− 65.3 (− 82.7, − 58.2)

0.020

4DST

preSUVmax

9.2 (5.9, 10.3)

6.8 (4.8, 8.5)

0.21

postSUVmax

3.3 (2.9, 5.2)

6.7 (5.7, 7.8)

0.001

 ΔSUVmax (%)

− 56.7 (− 65.6, − 40.8)

− 2.9 (− 10.5, 15.9)

< 0.001

preMTV

17.8 (9.7, 36.9)

15.1 (3.4, 34.9)

0.53

postMTV

2.1 (1.4, 3.6)

4.0 (1.6, 10.5)

0.43

 ΔMTV (%)

− 86.9 (− 92.0, − 72.9)

− 54.3 (− 75.1, − 25.1)

0.11

preTLP

66.9 (37.1, 201.9)

48.8 (15.5, 88.0)

0.34

postTLP

5.3 (2.9, 10.9)

11.9 (6.5, 34.1)

0.102

 ΔTLP (%)

− 91.6 (− 95.1, − 87.0)

− 54.4 (− 75.6, − 2.3)

0.020

  1. SUVmax maximum standardized uptake value, MTV metabolic tumor volume, TLG total lesion glycolysis, TLP total lesion proliferation